Latest Regulatory Risk News

Harvey Norman Holdings Limited reported strong FY25 financial results, driven by growth in franchisee sales, property portfolio appreciation, and digital investments. The company’s integrated retail, franchise, property, and digital system across multiple countries underpins its sustained shareholder returns.

The Star Entertainment Group reported a challenging FY25 with a $471.5 million statutory net loss and a $77.1 million EBITDA loss before significant items, driven by regulatory reforms and market share declines. The group secured a $300 million strategic investment to support its turnaround efforts amid ongoing legal and licensing uncertainties.

The Star Entertainment Group reported a $471.5 million net loss for FY25, marking a 72% improvement from the prior year but underscored by ongoing regulatory challenges and a complex joint venture exit.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

AF Legal Group has reported a record-breaking FY25 with revenue up 27% to $27.6 million and a 77% jump in normalised profit before tax. The firm’s strategic acquisitions and operational improvements set a positive tone for FY26 growth.

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.

Evolution Energy Minerals has disclosed a default notice from Tanzanian regulators over delayed mining commencement, yet remains confident in retaining its key graphite mining license.

Cettire Limited reported FY25 results showing stable sales revenue and a breakeven adjusted EBITDA despite a challenging luxury goods market. The company’s strategic focus on profitability, supply chain expansion, and emerging markets diversification underpins its resilience.

Nexion Group has agreed to sell its telecommunications subsidiaries for $4.1 million, aiming to reduce debt and pivot towards its high-growth AI and business intelligence operations.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Helix Resources Limited’s HLXOA securities have been suspended from trading pending regulatory compliance, raising questions about the company’s immediate outlook.